{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:43:28Z","timestamp":1786160608907,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019035","name":"Hubei Province Science and Technology Program","doi-asserted-by":"publisher","award":["2024KFZ015"],"award-info":[{"award-number":["2024KFZ015"]}],"id":[{"id":"10.13039\/501100019035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017958","name":"Health Commission of Hubei Province","doi-asserted-by":"publisher","award":["[2019]47"],"award-info":[{"award-number":["[2019]47"]}],"id":[{"id":"10.13039\/100017958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.intimp.2025.115158","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:47:48Z","timestamp":1751395668000},"page":"115158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of \u03b2-catenin to attenuate ovarian cancer invasion and metastasis"],"prefix":"10.1016","volume":"162","author":[{"given":"Jiaxin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqi","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115158_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.intimp.2025.115158_bb0010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1186\/s12885-021-08537-6","article-title":"Exploring the malnutrition status and impact of total parenteral nutrition on the outcome of patients with advanced stage ovarian cancer","volume":"21","author":"Yan","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115158_bb0015","article-title":"Ovarian Cancer-Insights into Platinum Resistance and Overcoming it","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"8","key":"10.1016\/j.intimp.2025.115158_bb0020","first-page":"3599","article-title":"Effect of different metastasis patterns on the prognosis of patients with stage III high-grade serous ovarian cancer","volume":"13","author":"Yang","year":"2023","journal-title":"Am. J. Cancer Res."},{"issue":"17","key":"10.1016\/j.intimp.2025.115158_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174405","article-title":"Niraparib suppresses cholangiocarcinoma tumor growth by inducing oxidative and replication stress","volume":"13","author":"Bezrookove","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2025.115158_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101928","article-title":"PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer","volume":"42","author":"Hong","year":"2021","journal-title":"Redox Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115158_bb0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2025.115158_bb0045","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","article-title":"Fuzuloparib: First Approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.intimp.2025.115158_bb0050","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/cas.13947","article-title":"Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials","volume":"110","author":"Wang","year":"2019","journal-title":"Cancer Sci."},{"issue":"20","key":"10.1016\/j.intimp.2025.115158_bb0055","doi-asserted-by":"crossref","first-page":"15822","DOI":"10.1021\/acs.chemrev.1c01006","article-title":"Demystifying the O-GlcNAc code: a systems view","volume":"122","author":"Ma","year":"2022","journal-title":"Chem. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2025.115158_bb0060","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.115158_bb0065","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1146\/annurev-biochem-060608-102511","article-title":"Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease","volume":"80","author":"Hart","year":"2011","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.intimp.2025.115158_bb0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1039\/D2RA07184C","article-title":"Recent development of analytical methods for disease-specific protein O-GlcNAcylation","volume":"13","author":"Hu","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.intimp.2025.115158_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.sbi.2018.12.003","article-title":"Structural characterization of the O-GlcNAc cycling enzymes: insights into substrate recognition and catalytic mechanisms","volume":"56","author":"Joiner","year":"2019","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115158_bb0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nchembio.797","article-title":"Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation","volume":"8","author":"Yuzwa","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.intimp.2025.115158_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155062","article-title":"Icaritin inhibits endometrial carcinoma cells by suppressing O-GlcNAcylation of FOXC1","volume":"120","author":"Wang","year":"2023","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.intimp.2025.115158_bb0090","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.bbrc.2017.11.179","article-title":"Elevated O-GlcNAcylation stabilizes FOXM1 by its reduced degradation through GSK-3\u03b2 inactivation in a human gastric carcinoma cell line, MKN45 cells","volume":"495","author":"Inoue","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2025.115158_bb0095","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1074\/jbc.M116.763201","article-title":"O-linked N-Acetylglucosamine (O-GlcNAc) expression levels epigenetically regulate Colon Cancer tumorigenesis by affecting the Cancer stem cell compartment via modulating expression of transcriptional factor MYBL1","volume":"292","author":"Guo","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2025.115158_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032142","article-title":"Emerging role of protein O-GlcNAcylation in liver metabolism: implications for diabetes and NAFLD","volume":"24","author":"Xie","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115158_bb0105","article-title":"GOLPH3 and oncogenesis: what is the molecular link?","volume":"49(2 Pt A):170-174","author":"Rizzo","year":"2017","journal-title":"Tissue Cell"},{"issue":"7","key":"10.1016\/j.intimp.2025.115158_bb0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/iub.2806","article-title":"Wnt signaling in cell adhesion, development, and colon cancer","volume":"76","author":"Tejeda-Mu\u00f1oz","year":"2024","journal-title":"IUBMB Life"},{"issue":"3","key":"10.1016\/j.intimp.2025.115158_bb0115","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.7150\/thno.79318","article-title":"PLK1-mediated phosphorylation of \u03b2-catenin enhances its stability and transcriptional activity for extracellular matrix remodeling in metastatic NSCLC","volume":"13","author":"Kim","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2025.115158_bb0125","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphar.2020.00170","article-title":"Poly(ADP-ribose)polymerase (PARP) inhibitors and radiation therapy","volume":"11","author":"Jannetti","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115158_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors--moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115158_bb0135","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e86","article-title":"Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective","volume":"33","author":"Li","year":"2022","journal-title":"J. Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115158_bb0145","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/bcp.15256","article-title":"Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers","volume":"88","author":"Bian","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115158_bb0140","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-20-3546","article-title":"An open-label, multicenter, single-arm, phase II study of Fluzoparib in patients with germline BRCA1\/2 mutation and platinum-sensitive recurrent ovarian Cancer","volume":"27","author":"Li","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.115158_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105344","article-title":"On a sugar high: role of O-GlcNAcylation in cancer","volume":"299","author":"Le Minh","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"30","key":"10.1016\/j.intimp.2025.115158_bb0155","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1038\/s41388-021-01901-7","article-title":"OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"issue":"14","key":"10.1016\/j.intimp.2025.115158_bb0160","doi-asserted-by":"crossref","first-page":"11070","DOI":"10.1074\/jbc.M111.302547","article-title":"Critical role of O-linked \u03b2-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis","volume":"287","author":"Lynch","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.intimp.2025.115158_bb0165","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1158\/0008-5472.CAN-09-1887","article-title":"GlcNAcylation plays an essential role in breast cancer metastasis","volume":"70","author":"Gu","year":"2010","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2025.115158_bb0170","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41419-018-0961-7","article-title":"O-GlcNAcylation on Rab3A attenuates its effects on mitochondrial oxidative phosphorylation and metastasis in hepatocellular carcinoma","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.intimp.2025.115158_bb0175","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41388-018-0435-5","article-title":"O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc\/EZH2 regulatory feedback circuit","volume":"38","author":"Jiang","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.intimp.2025.115158_bb0180","doi-asserted-by":"crossref","first-page":"2251696","DOI":"10.1080\/21655979.2023.2251696","article-title":"\u0392-Catenin inhibitors in cancer therapeutics: intricacies and way forward","volume":"14","author":"Dev","year":"2023","journal-title":"Bioengineered"},{"key":"10.1016\/j.intimp.2025.115158_bb0185","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/CMAR.S411168","article-title":"Wnt\/\u03b2-catenin signaling pathway in the development and progression of colorectal Cancer","volume":"15","author":"He","year":"2023","journal-title":"Cancer Manag. Res."},{"issue":"21","key":"10.1016\/j.intimp.2025.115158_bb0190","first-page":"7492","article-title":"Curcumin inhibits the growth via Wnt\/\u03b2-catenin pathway in non-small-cell lung cancer cells","volume":"22","author":"Wang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.intimp.2025.115158_bb0195","article-title":"Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates cytokinesis","volume":"3(104):ra2","author":"Wang","year":"2010","journal-title":"Sci. Signal."},{"issue":"12","key":"10.1016\/j.intimp.2025.115158_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152681","article-title":"Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of \u03b2-catenin","volume":"215","author":"Zhou","year":"2019","journal-title":"Pathol. Res. Pract."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925011488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:13:54Z","timestamp":1786158834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925011488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S1567576925011488"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115158","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluzoparib disrupts Golgi apparatus to inhibit O-GlcNAcylation and nuclear translocation of \u03b2-catenin to attenuate ovarian cancer invasion and metastasis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115158"}}